about
Antagonist treatment of opioid withdrawal translational low dose approachPentylenetetrazol produces a state-dependent conditioned place aversion to alcohol withdrawal in miceDrug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine.Consilience of rodent and human phenotypes relevant for alcohol dependence.Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signsDecreased brain reward produced by ethanol withdrawalEvaluation of the Anxiolytic Activity of NR-ANX-C (a Polyherbal Formulation) in Ethanol Withdrawal-Induced Anxiety Behavior in RatsTolerance to the rate-increasing and not rate-decreasing effects of pregnanolone in ratsAgonist-antagonist combinations in opioid dependence: a translational approachAttenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration.Reinforcement processes in opiate addiction: a homeostatic model.Role of calcium in morphine dependence and naloxone-precipitated withdrawal in mice.The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.The rise (and fall?) of drug discrimination research.Evaluation of anxiolytic action of ondansetron in rats during withdrawal from chronic chlordiazepoxide.Effects of chronic ethanol exposure on oral self-administration of ethanol or saccharin by Wistar rats.Conditioned Taste Avoidance Drug Discrimination Procedure: Assessments and Applications.Effect of pentylenetetrazole on ethanol intake, ethanol kinetics, and social behavior in male Wistar rats.
P2860
Q28247052-62782E19-999A-477D-BD67-A001B54A1CC5Q30476112-1235BFA8-6412-4501-93B7-30BFF2F15501Q33692842-A4004888-21F8-42F9-99DB-AD525A311AFBQ33784674-D5101A71-A910-4F90-A2BC-E1DF8462B38FQ34028114-31AEFB7D-90F5-4AA2-9458-CFA0DCA1A0EBQ34161433-2DD27DEC-BBC3-4942-8496-121F7B15EA99Q34186853-DC592C07-F1BB-41F3-89B1-9752F439E42FQ34538484-D63802B5-09A3-4677-8CBD-FDC1E45A946AQ35848930-6BAEE583-331F-4959-8A6E-7B1C1199F76EQ36233639-536B084A-88FC-4AD5-8971-45D88F2B2450Q41247900-B1E3107F-80CB-4DA5-B638-ED1E708E8796Q41350890-E727DFA5-B272-426E-BA6C-2CDDCC30CDE5Q42003959-D19D6C58-C79E-494E-8178-6E91BC6CAFCAQ42762761-240BC10B-DC45-4708-861C-0FEBB7E3DFACQ43864129-826C9E44-8C93-4F7F-A5A7-44E29C2A93E0Q46498867-F23B695A-03BB-4716-B6B4-698C2E67B071Q50509709-A74D930B-7B85-4262-BCB3-DFEE4B3F0D57Q51097831-942D63AA-07D4-411D-B021-B4A17EA5D53C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Animal models of drug withdrawal symptoms.
@en
Animal models of drug withdrawal symptoms.
@nl
type
label
Animal models of drug withdrawal symptoms.
@en
Animal models of drug withdrawal symptoms.
@nl
prefLabel
Animal models of drug withdrawal symptoms.
@en
Animal models of drug withdrawal symptoms.
@nl
P2093
P2860
P356
P1433
P1476
Animal models of drug withdrawal symptoms.
@en
P2093
D A Mathis
M W Emmett-Oglesby
P2860
P2888
P304
P356
10.1007/BF02244046
P577
1990-01-01T00:00:00Z